662 related articles for article (PubMed ID: 35095898)
61. Lynch syndrome-associated epithelial ovarian cancer and its immunological profile.
Rasmussen M; Lim K; Rambech E; Andersen MH; Svane IM; Andersen O; Jensen LH; Nilbert M; Therkildsen C
Gynecol Oncol; 2021 Sep; 162(3):686-693. PubMed ID: 34275654
[TBL] [Abstract][Full Text] [Related]
62. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers.
Schwitalle Y; Kloor M; Eiermann S; Linnebacher M; Kienle P; Knaebel HP; Tariverdian M; Benner A; von Knebel Doeberitz M
Gastroenterology; 2008 Apr; 134(4):988-97. PubMed ID: 18395080
[TBL] [Abstract][Full Text] [Related]
63. Immunotherapy for the treatment of colorectal cancer.
Lumish MA; Cercek A
J Surg Oncol; 2021 Mar; 123(3):760-774. PubMed ID: 33595891
[TBL] [Abstract][Full Text] [Related]
64. Subtyping of microsatellite stability colorectal cancer reveals guanylate binding protein 2 (GBP2) as a potential immunotherapeutic target.
Wang H; Zhou Y; Zhang Y; Fang S; Zhang M; Li H; Xu F; Liu L; Liu J; Zhao Q; Wang F
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35383115
[TBL] [Abstract][Full Text] [Related]
65. An Insight into Deficient Mismatch Repair Colorectal Cancer Screening in a Romanian Population-A Bi-Institutional Pilot Study.
Lungulescu C; Croitoru VM; Volovat SR; Cazacu IM; Turcu-Stiolica A; Gheonea DI; Sur D; Lungulescu CV
Medicina (Kaunas); 2021 Aug; 57(8):. PubMed ID: 34441055
[No Abstract] [Full Text] [Related]
66. Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications.
Solinas C; Pusole G; Demurtas L; Puzzoni M; Mascia R; Morgan G; Giampieri R; Scartozzi M
Crit Rev Oncol Hematol; 2017 Feb; 110():106-116. PubMed ID: 28109400
[TBL] [Abstract][Full Text] [Related]
67. Fas ligand and tumour counter-attack in colorectal cancer stratified according to microsatellite instability status.
Michael-Robinson JM; Pandeya N; Cummings MC; Walsh MD; Young JP; Leggett BA; Purdie DM; Jass JR; Radford-Smith GL
J Pathol; 2003 Sep; 201(1):46-54. PubMed ID: 12950016
[TBL] [Abstract][Full Text] [Related]
68. Meta-analysis of neoadjuvant immunotherapy for non-metastatic colorectal cancer.
Zhou L; Yang XQ; Zhao GY; Wang FJ; Liu X
Front Immunol; 2023; 14():1044353. PubMed ID: 36776899
[TBL] [Abstract][Full Text] [Related]
69. Tumor-infiltrating lymphocytes in the immunotherapy era.
Paijens ST; Vledder A; de Bruyn M; Nijman HW
Cell Mol Immunol; 2021 Apr; 18(4):842-859. PubMed ID: 33139907
[TBL] [Abstract][Full Text] [Related]
70. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
[TBL] [Abstract][Full Text] [Related]
71. Relationship between T cell receptor clonotype and PD-1 expression of tumor-infiltrating lymphocytes in colorectal cancer.
Sukegawa K; Shitaoka K; Hamana H; Kobayashi E; Miyahara Y; Fujii K; Tsuda K; Saeki S; Nagata T; Ozawa T; Saito S; Fujii T; Muraguchi A; Shiku H; Kishi H
Eur J Immunol; 2020 Oct; 50(10):1580-1590. PubMed ID: 32441316
[TBL] [Abstract][Full Text] [Related]
72. Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer.
Akin Telli T; Bregni G; Vanhooren M; Saude Conde R; Hendlisz A; Sclafani F
Cancer Treat Rev; 2022 Nov; 110():102460. PubMed ID: 36058142
[TBL] [Abstract][Full Text] [Related]
73. Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability.
Korehisa S; Oki E; Iimori M; Nakaji Y; Shimokawa M; Saeki H; Okano S; Oda Y; Maehara Y
Int J Cancer; 2018 Feb; 142(4):822-832. PubMed ID: 29044503
[TBL] [Abstract][Full Text] [Related]
74. Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome.
Araujo B de Lima V; Borch A; Hansen M; Draghi A; Spanggaard I; Rohrberg K; Reker Hadrup S; Lassen U; Svane IM
Cytotherapy; 2020 Apr; 22(4):204-213. PubMed ID: 32201034
[TBL] [Abstract][Full Text] [Related]
75. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
McArthur HL; Page DB
Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
[TBL] [Abstract][Full Text] [Related]
76. Association of Germline Variants in Natural Killer Cells With Tumor Immune Microenvironment Subtypes, Tumor-Infiltrating Lymphocytes, Immunotherapy Response, Clinical Outcomes, and Cancer Risk.
Xu X; Li J; Zou J; Feng X; Zhang C; Zheng R; Duanmu W; Saha-Mandal A; Ming Z; Wang E
JAMA Netw Open; 2019 Sep; 2(9):e199292. PubMed ID: 31483464
[TBL] [Abstract][Full Text] [Related]
77. Checkpoint blockade-based immunotherapy in the context of tumor microenvironment: Opportunities and challenges.
Duan J; Wang Y; Jiao S
Cancer Med; 2018 Sep; 7(9):4517-4529. PubMed ID: 30088347
[TBL] [Abstract][Full Text] [Related]
78. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
[TBL] [Abstract][Full Text] [Related]
79. Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a
Gong J; Wang C; Lee PP; Chu P; Fakih M
J Natl Compr Canc Netw; 2017 Feb; 15(2):142-147. PubMed ID: 28188185
[TBL] [Abstract][Full Text] [Related]
80. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]